Sibrotuzumab

CAS No. 216669-97-5

Sibrotuzumab( —— )

Catalog No. M36723 CAS No. 216669-97-5

Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targeting Fibroblast Activating Protein (FAP) and is used in the study of colorectal cancer and non-small cell lung cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 630 Get Quote
10MG 1007 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Sibrotuzumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targeting Fibroblast Activating Protein (FAP) and is used in the study of colorectal cancer and non-small cell lung cancer.
  • Description
    Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    216669-97-5
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Scott AM, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47.?
molnova catalog
related products
  • Kemptide TFA (65189-...

    Kemptide TFA is a synthetic heptapeptide, acting as a substrate for cAMP-dependent protein kinase (PK).

  • Ensituximab

    Ensituximab (NEO-102) is a quasi-selective IgG1 monoclonal antibody against the MUC5AC variant with anti-tumour activity that inhibits colorectal and pancreatic cancer.

  • PDD00017272

    PDD00017272 (34f) is a potent inhibitor of poly(ADP-ribose) glycohydrolase (PARG), exhibiting an EC50 value of 4.8 nM in biochemical assays and 9.2 nM in cellular POM.